Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
ESMO Congress 2026 · Barcelona, Spain
200 shown of 2,319 total abstracts
  1. Abstract 17102026-09-05 · 15:00 CT · Arie Crown Theater
    Lynparza plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from OlympiA-483
    C. Saura, M. Reck, P. Schmid · MD Anderson Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  2. Abstract 15432026-09-01 · 15:45 CT · E450
    Quality of life outcomes with Trodelvy in patients with TNBC
    R. Herbst, P. Schmid, A. Spira · Princess Margaret Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  3. Abstract 14552026-09-03 · 13:45 CT · S100A
    Quality of life outcomes with Kisqali in patients with HR+ breast cancer
    J. Brahmer, C. Saura, R. Herbst, et al. · Stanford Cancer Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  4. Abstract 10812026-09-04 · 20:00 CT · S100A
    Real-world effectiveness of Enhertu vs standard of care in HR+ breast cancer
    S. Modi, M. Krop, E. Winer, et al. · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  5. Abstract 16882026-09-01 · 20:00 CT · Hall B1
    Real-world effectiveness of Ibrance vs standard of care in HR+ breast cancer
    S. Peters, G. Curigliano, E. Winer, et al. · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  6. Abstract 17292026-09-01 · 21:00 CT · S100A
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-665
    G. Curigliano, C. Robert, M. Krop, et al. · Princess Margaret Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  7. Abstract 11272026-09-05 · 18:15 CT · E450
    Quality of life outcomes with Keytruda in patients with TNBC
    M. Reck, C. Saura · Karolinska Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  8. Abstract 14382026-09-04 · 21:30 CT · Hall B1
    Real-world effectiveness of Verzenio vs standard of care in HR+ breast cancer
    R. Herbst, M. Krop · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  9. Abstract 12852026-09-03 · 21:15 CT · Hall B1
    Quality of life outcomes with Lynparza in patients with HR+ breast cancer
    S. Antonia, R. Herbst, J. Brahmer, et al. · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  10. Abstract 15062026-09-01 · 14:45 CT · Arie Crown Theater
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-891
    S. Tolaney, M. Reck, R. Herbst, et al. · University of Chicago
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  11. Abstract 10452026-09-05 · 16:30 CT · Hall B1
    DESTINY-Breast-159: Enhertu (trastuzumab deruxtecan) 1L in HR+ breast cancer
    S. Modi, R. Herbst, H. Rugo, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  12. Abstract 11482026-09-03 · 18:15 CT · E450
    Long-term follow-up of Verzenio adjuvant for HR+ breast cancer: MONARCH-366
    C. Robert, S. Modi, P. Schmid, et al. · Massachusetts General Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  13. Abstract TPS80122026-09-03 · 13:45 CT · S406
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-315
    M.C. Garassino, C. Robert, H. Borghaei, et al. · Princess Margaret Cancer Centre
    Trials in Progress Poster SessionBreast Cancer—Metastatic📄🖼️
  14. Abstract LBA4013LBA2026-09-03 · 19:30 CT · Hall B1
    PALOMA-606: Ibrance (palbociclib) neoadjuvant in HR+ breast cancer
    S. Modi, R. Herbst · Karolinska Institute
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  15. Abstract 11512026-09-03 · 14:45 CT · E450
    DESTINY-Breast-763: Enhertu (trastuzumab deruxtecan) 1L in HR+ breast cancer
    M. Krop, N. Rizvi, R. Herbst · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  16. Abstract 14372026-09-03 · 13:15 CT · S406
    PALOMA-908: Ibrance (palbociclib) 3L+ in HR+ breast cancer
    C. Robert, P. Schmid, R. Herbst · Institut Gustave Roussy
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  17. Abstract LBA4016LBA2026-09-01 · 19:30 CT · S406
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-458
    H. Rugo, M. Krop, L. Paz-Ares, et al. · Institut Gustave Roussy
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  18. Abstract 13762026-09-03 · 19:15 CT · Hall B1
    MONALEESA-279: Kisqali (ribociclib) 1L in HR+ breast cancer
    C. Saura, F. Andre, M. Reck, et al. · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  19. Abstract 12992026-09-05 · 20:15 CT · Hall B1
    Quality of life outcomes with Tecentriq in patients with TNBC
    C. Saura, M. Krop · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  20. Abstract 19402026-09-03 · 14:45 CT · E450
    Long-term follow-up of Tecentriq maintenance for TNBC: IMpower-963
    P. Schmid, C. Saura, L. Paz-Ares · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  21. Abstract 12662026-09-02 · 20:00 CT · S406
    Long-term follow-up of Trodelvy maintenance for TNBC: ASCENT-906
    L. Paz-Ares, M. Krop, F. Andre, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  22. Abstract 16422026-09-01 · 21:00 CT · Hall B1
    Long-term follow-up of Tecentriq adjuvant for TNBC: IMpower-896
    C. Robert, M. Reck · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  23. Abstract 12292026-09-01 · 15:15 CT · E450
    MONALEESA-674: Kisqali (ribociclib) neoadjuvant in HR+ breast cancer
    E. Winer, J. Brahmer, G. Curigliano, et al. · Peter MacCallum Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  24. Abstract TPS80232026-09-01 · 13:00 CT · Arie Crown Theater
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-710
    N. Rizvi, C. Saura, J. Brahmer, et al. · Royal Marsden Hospital
    Trials in Progress Poster SessionBreast Cancer—Metastatic📄🖼️
  25. Abstract 17752026-09-01 · 16:15 CT · E450
    Long-term follow-up of Kisqali adjuvant for HR+ breast cancer: MONALEESA-852
    M. Reck, S. Modi · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  26. Abstract 12382026-09-02 · 18:00 CT · E450
    IMpower-342: Tecentriq (atezolizumab) maintenance in TNBC
    L. Paz-Ares, J. Cortes, M. Reck · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  27. Abstract 18412026-09-02 · 13:45 CT · Arie Crown Theater
    Lynparza plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from OlympiA-786
    J. Cortes, M. Reck, J. Brahmer, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  28. Abstract TPS80272026-09-02 · 13:15 CT · E450
    DESTINY-Breast-271: Enhertu (trastuzumab deruxtecan) maintenance in HR+ breast cancer
    G. Curigliano, R. Herbst, M.C. Garassino · Memorial Sloan Kettering Cancer Center
    Trials in Progress Poster SessionBreast Cancer—Metastatic📄🖼️
  29. Abstract 11892026-09-01 · 16:30 CT · S100A
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-975
    P. Schmid, J. Brahmer, S. Tolaney · Institut Gustave Roussy
    Poster SessionBreast Cancer—Metastatic📄🖼️
  30. Abstract 13742026-09-03 · 19:45 CT · E450
    Quality of life outcomes with Enhertu in patients with HR+ breast cancer
    S. Tolaney, S. Modi · Chinese University of Hong Kong
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  31. Abstract 19882026-09-03 · 13:00 CT · S406
    Quality of life outcomes with Ibrance in patients with HR+ breast cancer
    N. Rizvi, M. Reck · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  32. Abstract 16632026-09-03 · 14:00 CT · Hall B1
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-137
    J. Brahmer, G. Curigliano, H. Rugo, et al. · Royal Marsden Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  33. Abstract 18092026-09-02 · 14:45 CT · S406
    PALOMA-582: Ibrance (palbociclib) adjuvant in HR+ breast cancer
    L. Paz-Ares, C. Robert · Peter MacCallum Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  34. Abstract 10792026-09-05 · 15:15 CT · S406
    Long-term follow-up of Ibrance 2L for HR+ breast cancer: PALOMA-572
    E. Winer, S. Tolaney · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  35. Abstract 13712026-09-03 · 21:00 CT · Arie Crown Theater
    PALOMA-540: Ibrance (palbociclib) 2L in HR+ breast cancer
    N. Rizvi, J. Brahmer, L. Paz-Ares, et al. · MD Anderson Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  36. Abstract 13022026-09-02 · 20:00 CT · Arie Crown Theater
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-660
    C. Saura, P. Schmid · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  37. Abstract 14862026-09-05 · 15:30 CT · S100A
    KEYNOTE-740: Keytruda (pembrolizumab) 2L in TNBC
    M. Reck, E. Winer · National Cancer Center Japan
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  38. Abstract LBA4037LBA2026-09-05 · 16:15 CT · Hall B1
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-110
    C. Saura, E. Winer · Massachusetts General Hospital
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  39. Abstract 10822026-09-05 · 20:15 CT · S100A
    Real-world effectiveness of Trodelvy vs standard of care in TNBC
    E. Winer, N. Rizvi, L. Paz-Ares, et al. · National Cancer Center Japan
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  40. Abstract 15412026-09-01 · 20:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-135 study)
    S. Tolaney, C. Robert, S. Peters, et al. · Johns Hopkins Kimmel Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  41. Abstract LBA4040LBA2026-09-03 · 13:15 CT · Hall B1
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-821 study)
    S. Peters, H. Borghaei, P. Schmid · Massachusetts General Hospital
    Late-Breaking Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  42. Abstract 19422026-09-05 · 18:30 CT · S100A
    MONALEESA-270: Kisqali (ribociclib) maintenance in HR+ breast cancer
    S. Tolaney, L. Paz-Ares, F. Andre, et al. · University of Chicago
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  43. Abstract 16692026-09-02 · 21:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-142 study)
    H. Rugo, L. Paz-Ares, P. Schmid, et al. · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  44. Abstract 12872026-09-02 · 18:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-423 study)
    P. Schmid, C. Saura, A. Spira · Chinese University of Hong Kong
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  45. Abstract 17922026-09-02 · 15:15 CT · S406
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-612 study)
    F. Andre, R. Herbst, M.C. Garassino, et al. · MD Anderson Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  46. Abstract 19762026-09-05 · 20:45 CT · S406
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-146
    J. Cortes, H. Borghaei, M. Krop · Chinese University of Hong Kong
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  47. Abstract 15822026-09-04 · 20:00 CT · S100A
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-886
    S. Tolaney, E. Winer, S. Peters, et al. · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  48. Abstract 15572026-09-03 · 15:15 CT · Hall B1
    DESTINY-Breast-366: Enhertu (trastuzumab deruxtecan) adjuvant in HR+ breast cancer
    H. Borghaei, J. Cortes, S. Tolaney · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  49. Abstract e120482026-09-02 · 21:30 CT · Arie Crown Theater
    Long-term follow-up of Kisqali 1L for HR+ breast cancer: MONALEESA-263
    S. Peters, L. Paz-Ares, J. Cortes · UCSF Helen Diller Family Comprehensive Cancer Center
    Publication OnlyBreast Cancer—Metastatic📄🖼️
  50. Abstract 17682026-09-05 · 15:45 CT · Hall B1
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-696
    P. Schmid, S. Modi · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  51. Abstract 10762026-09-05 · 21:15 CT · S406
    OlympiA-547: Lynparza (olaparib) 2L in HR+ breast cancer
    L. Paz-Ares, T. Mok · National Cancer Center Japan
    Poster SessionBreast Cancer—Metastatic📄🖼️
  52. Abstract e120512026-09-04 · 18:45 CT · Arie Crown Theater
    Long-term follow-up of Kisqali 3L+ for HR+ breast cancer: MONALEESA-369
    S. Peters, N. Rizvi, M. Krop, et al. · Institut Gustave Roussy
    Publication OnlyBreast Cancer—Metastatic📄🖼️
  53. Abstract 18572026-09-04 · 18:15 CT · Arie Crown Theater
    MONARCH-897: Verzenio (abemaciclib) adjuvant in HR+ breast cancer
    S. Tolaney, P. Schmid, J. Brahmer, et al. · MD Anderson Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  54. Abstract 10852026-09-01 · 21:30 CT · Arie Crown Theater
    MONALEESA-409: Kisqali (ribociclib) 3L+ in HR+ breast cancer
    T. Mok, S. Tolaney, G. Curigliano · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  55. Abstract 12442026-09-02 · 16:00 CT · Hall B1
    MONARCH-18: Verzenio (abemaciclib) 3L+ in HR+ breast cancer
    C. Robert, H. Borghaei, S. Antonia, et al. · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  56. Abstract 16392026-09-03 · 14:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-615 study)
    E. Winer, T. Mok, S. Tolaney, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  57. Abstract TPS80562026-09-05 · 16:45 CT · Arie Crown Theater
    PALOMA-508: Ibrance (palbociclib) neoadjuvant in HR+ breast cancer
    J. Cortes, N. Rizvi, S. Tolaney · Massachusetts General Hospital
    Trials in Progress Poster SessionBreast Cancer—Metastatic📄🖼️
  58. Abstract 16762026-09-02 · 13:45 CT · Arie Crown Theater
    DESTINY-Breast-246: Enhertu (trastuzumab deruxtecan) 1L in HR+ breast cancer
    S. Tolaney, A. Spira · National Cancer Center Japan
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  59. Abstract 12682026-09-03 · 19:45 CT · E450
    Real-world effectiveness of Lynparza vs standard of care in HR+ breast cancer
    M. Krop, H. Rugo · Princess Margaret Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  60. Abstract 18132026-09-02 · 14:30 CT · E450
    Quality of life outcomes with Verzenio in patients with HR+ breast cancer
    G. Curigliano, A. Spira, E. Winer · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  61. Abstract 11212026-09-04 · 15:15 CT · S406
    Tecentriq plus chemotherapy in previously untreated TNBC: updated analysis from IMpower-63
    L. Paz-Ares, H. Borghaei, S. Antonia · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  62. Abstract 14912026-09-01 · 20:00 CT · S406
    Biomarker subgroup analysis of Lynparza in HR+ breast cancer (the OlympiA-296 study)
    M. Reck, H. Rugo, S. Modi, et al. · Cleveland Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  63. Abstract 11292026-09-03 · 18:15 CT · Arie Crown Theater
    MONARCH-329: Verzenio (abemaciclib) adjuvant in HR+ breast cancer
    H. Borghaei, S. Peters · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  64. Abstract 13382026-09-02 · 15:15 CT · E450
    MONARCH-27: Verzenio (abemaciclib) neoadjuvant in HR+ breast cancer
    F. Andre, M. Reck, C. Saura · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  65. Abstract 14952026-09-05 · 20:30 CT · S406
    MONARCH-823: Verzenio (abemaciclib) 2L in HR+ breast cancer
    S. Peters, M. Krop, J. Cortes · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  66. Abstract 13392026-09-02 · 16:15 CT · S406
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-713
    M. Reck, M.C. Garassino, A. Spira, et al. · National Cancer Center Japan
    Poster SessionBreast Cancer—Metastatic📄🖼️
  67. Abstract 15112026-09-05 · 16:15 CT · S406
    Long-term follow-up of Trodelvy adjuvant for TNBC: ASCENT-738
    M. Reck, F. Andre, J. Cortes, et al. · Chinese University of Hong Kong
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  68. Abstract 19972026-09-01 · 20:45 CT · S100A
    Long-term follow-up of Enhertu adjuvant for HR+ breast cancer: DESTINY-Breast-411
    L. Paz-Ares, S. Tolaney, A. Spira, et al. · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  69. Abstract 10322026-09-05 · 13:15 CT · E450
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-108
    N. Rizvi, S. Antonia, J. Brahmer · Institut Gustave Roussy
    Poster SessionBreast Cancer—Metastatic📄🖼️
  70. Abstract 15002026-09-02 · 19:30 CT · Hall B1
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-65 study)
    N. Rizvi, M.C. Garassino · Institut Gustave Roussy
    Poster SessionBreast Cancer—Metastatic📄🖼️
  71. Abstract e120702026-09-02 · 15:45 CT · Hall B1
    MONALEESA-346: Kisqali (ribociclib) maintenance in HR+ breast cancer
    H. Rugo, E. Winer, T. Mok, et al. · Princess Margaret Cancer Centre
    Publication OnlyBreast Cancer—Metastatic📄🖼️
  72. Abstract 19192026-09-01 · 16:15 CT · Hall B1
    Long-term follow-up of Ibrance neoadjuvant for HR+ breast cancer: PALOMA-241
    L. Paz-Ares, M.C. Garassino, H. Rugo, et al. · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  73. Abstract 11442026-09-04 · 13:00 CT · E450
    MONALEESA-336: Kisqali (ribociclib) neoadjuvant in HR+ breast cancer
    A. Spira, P. Schmid, J. Cortes, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  74. Abstract 18782026-09-05 · 15:45 CT · Hall B1
    Long-term follow-up of Lynparza 1L for HR+ breast cancer: OlympiA-999
    M. Reck, S. Modi, H. Borghaei, et al. · MD Anderson Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  75. Abstract 18912026-09-02 · 16:00 CT · Arie Crown Theater
    ASCENT-807: Trodelvy (sacituzumab govitecan) 2L in TNBC
    F. Andre, A. Spira, E. Winer · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  76. Abstract 18742026-09-02 · 15:00 CT · Hall B1
    Real-world effectiveness of Kisqali vs standard of care in HR+ breast cancer
    G. Curigliano, C. Saura · Chinese University of Hong Kong
    Poster SessionBreast Cancer—Metastatic📄🖼️
  77. Abstract 19062026-09-04 · 21:00 CT · S406
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-905 study)
    S. Antonia, G. Curigliano, M. Krop, et al. · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  78. Abstract 12242026-09-03 · 13:00 CT · S100A
    Long-term follow-up of Ibrance 3L+ for HR+ breast cancer: PALOMA-162
    M.C. Garassino, P. Schmid, R. Herbst · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  79. Abstract 11612026-09-02 · 18:30 CT · E450
    ASCENT-897: Trodelvy (sacituzumab govitecan) adjuvant in TNBC
    T. Mok, R. Herbst, C. Robert, et al. · Karolinska Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  80. Abstract 14752026-09-02 · 18:30 CT · E450
    MONARCH-221: Verzenio (abemaciclib) adjuvant in HR+ breast cancer
    C. Saura, M. Krop, E. Winer, et al. · Peter MacCallum Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  81. Abstract 19952026-09-01 · 21:00 CT · Hall B1
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-232
    J. Cortes, M. Krop, S. Peters, et al. · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  82. Abstract 18752026-09-04 · 18:15 CT · S100A
    ASCENT-168: Trodelvy (sacituzumab govitecan) neoadjuvant in TNBC
    A. Spira, N. Rizvi, S. Modi · Royal Marsden Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  83. Abstract 19292026-09-05 · 16:00 CT · E450
    Long-term follow-up of Verzenio maintenance for HR+ breast cancer: MONARCH-433
    N. Rizvi, J. Brahmer, L. Paz-Ares, et al. · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  84. Abstract 11492026-09-05 · 16:45 CT · S100A
    Long-term follow-up of Lynparza adjuvant for HR+ breast cancer: OlympiA-539
    F. Andre, S. Antonia, N. Rizvi, et al. · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  85. Abstract 11522026-09-04 · 18:00 CT · S406
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-114 study)
    C. Robert, P. Schmid, J. Brahmer, et al. · Princess Margaret Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  86. Abstract 12572026-09-04 · 16:30 CT · S406
    Tecentriq plus chemotherapy in previously untreated TNBC: updated analysis from IMpower-83
    H. Borghaei, M. Krop, S. Antonia, et al. · Massachusetts General Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  87. Abstract 16922026-09-02 · 14:15 CT · S406
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-424 study)
    S. Tolaney, S. Antonia, S. Modi, et al. · Stanford Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  88. Abstract 14182026-09-05 · 19:45 CT · Hall B1
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-611 study)
    T. Mok, S. Modi, S. Peters, et al. · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  89. Abstract 11362026-09-03 · 19:00 CT · Arie Crown Theater
    Long-term follow-up of Kisqali neoadjuvant for HR+ breast cancer: MONALEESA-257
    M. Reck, J. Cortes, N. Rizvi, et al. · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  90. Abstract 10122026-09-04 · 16:30 CT · S100A
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-380 study)
    S. Modi, J. Brahmer, H. Rugo, et al. · Princess Margaret Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  91. Abstract 19132026-09-01 · 18:00 CT · Hall B1
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-99
    P. Schmid, J. Brahmer, C. Saura, et al. · Massachusetts General Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  92. Abstract 19692026-09-04 · 21:45 CT · S100A
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-30 study)
    M. Reck, M. Krop, F. Andre, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  93. Abstract 18222026-09-04 · 16:15 CT · S406
    Real-world effectiveness of Tecentriq vs standard of care in TNBC
    J. Cortes, M. Reck, M.C. Garassino · MD Anderson Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  94. Abstract 18802026-09-04 · 21:00 CT · E450
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-386 study)
    C. Robert, R. Herbst, M. Reck, et al. · Stanford Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  95. Abstract 19112026-09-03 · 20:15 CT · S100A
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-233
    H. Borghaei, M. Reck, G. Curigliano, et al. · MD Anderson Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  96. Abstract 18492026-09-04 · 19:15 CT · S406
    MONALEESA-854: Kisqali (ribociclib) neoadjuvant in HR+ breast cancer
    R. Herbst, H. Rugo, P. Schmid · Massachusetts General Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  97. Abstract e120962026-09-05 · 18:30 CT · S406
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-995
    S. Antonia, M.C. Garassino, M. Krop, et al. · Princess Margaret Cancer Centre
    Publication OnlyBreast Cancer—Metastatic📄🖼️
  98. Abstract 18872026-09-02 · 16:00 CT · Hall B1
    MONALEESA-625: Kisqali (ribociclib) 3L+ in HR+ breast cancer
    T. Mok, M. Krop, N. Rizvi · MD Anderson Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  99. Abstract 11812026-09-04 · 16:30 CT · S100A
    Long-term follow-up of Kisqali 3L+ for HR+ breast cancer: MONALEESA-906
    J. Brahmer, N. Rizvi, M. Reck, et al. · Massachusetts General Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  100. Abstract 17432026-09-02 · 21:45 CT · S100A
    Long-term follow-up of Kisqali 2L for HR+ breast cancer: MONALEESA-755
    S. Peters, J. Brahmer · Peter MacCallum Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  101. Abstract 18192026-09-01 · 15:15 CT · S406
    ASCENT-525: Trodelvy (sacituzumab govitecan) maintenance in TNBC
    S. Peters, T. Mok · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  102. Abstract 13052026-09-01 · 20:30 CT · S406
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-320
    P. Schmid, R. Herbst, C. Robert, et al. · National Cancer Center Japan
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  103. Abstract 15012026-09-05 · 21:00 CT · S100A
    IMpower-847: Tecentriq (atezolizumab) maintenance in TNBC
    C. Robert, N. Rizvi, M. Reck, et al. · Peter MacCallum Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  104. Abstract 18372026-09-04 · 14:45 CT · Hall B1
    MONARCH-622: Verzenio (abemaciclib) neoadjuvant in HR+ breast cancer
    L. Paz-Ares, M. Krop, H. Rugo, et al. · University of Chicago
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  105. Abstract 16892026-09-02 · 14:00 CT · S100A
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-71
    T. Mok, G. Curigliano, R. Herbst, et al. · Peter MacCallum Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  106. Abstract 10542026-09-04 · 21:45 CT · S100A
    Long-term follow-up of Verzenio maintenance for HR+ breast cancer: MONARCH-611
    R. Herbst, N. Rizvi, G. Curigliano · Royal Marsden Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  107. Abstract 11422026-09-02 · 19:15 CT · S100A
    MONALEESA-167: Kisqali (ribociclib) maintenance in HR+ breast cancer
    T. Mok, P. Schmid, J. Brahmer, et al. · MD Anderson Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  108. Abstract 18932026-09-04 · 16:30 CT · S100A
    MONALEESA-926: Kisqali (ribociclib) 1L in HR+ breast cancer
    G. Curigliano, M.C. Garassino, A. Spira · Dana-Farber Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  109. Abstract 18782026-09-02 · 15:15 CT · Arie Crown Theater
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-934
    J. Cortes, C. Robert · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  110. Abstract 10802026-09-04 · 21:15 CT · E450
    PALOMA-666: Ibrance (palbociclib) 1L in HR+ breast cancer
    C. Saura, L. Paz-Ares · Massachusetts General Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  111. Abstract 15292026-09-04 · 13:15 CT · E450
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-919 study)
    C. Robert, J. Cortes, R. Herbst · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  112. Abstract 15982026-09-02 · 14:30 CT · Hall B1
    Biomarker subgroup analysis of Enhertu in HR+ breast cancer (the DESTINY-Breast-878 study)
    M. Reck, C. Saura, M.C. Garassino · Princess Margaret Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  113. Abstract TPS81122026-09-02 · 19:45 CT · Hall B1
    Long-term follow-up of Verzenio 2L for HR+ breast cancer: MONARCH-83
    M.C. Garassino, P. Schmid, C. Saura, et al. · Dana-Farber Cancer Institute
    Trials in Progress Poster SessionBreast Cancer—Metastatic📄🖼️
  114. Abstract 10742026-09-04 · 21:00 CT · Arie Crown Theater
    Long-term follow-up of Trodelvy maintenance for TNBC: ASCENT-357
    S. Modi, S. Tolaney, G. Curigliano, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  115. Abstract 11572026-09-05 · 14:00 CT · Arie Crown Theater
    Tecentriq plus chemotherapy in previously untreated TNBC: updated analysis from IMpower-744
    M.C. Garassino, F. Andre · UCSF Helen Diller Family Comprehensive Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  116. Abstract 15572026-09-01 · 14:45 CT · S100A
    Long-term follow-up of Trodelvy neoadjuvant for TNBC: ASCENT-924
    J. Brahmer, R. Herbst · Institut Gustave Roussy
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  117. Abstract 16742026-09-05 · 21:15 CT · S100A
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-526 study)
    S. Peters, M. Reck, S. Antonia, et al. · Peter MacCallum Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  118. Abstract 13292026-09-02 · 16:00 CT · E450
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-780
    A. Spira, S. Peters, G. Curigliano · Massachusetts General Hospital
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  119. Abstract 15602026-09-04 · 19:30 CT · Hall B1
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-28 study)
    M.C. Garassino, P. Schmid, C. Robert, et al. · Institut Gustave Roussy
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  120. Abstract TPS81192026-09-01 · 13:45 CT · S100A
    Long-term follow-up of Lynparza 1L for HR+ breast cancer: OlympiA-702
    R. Herbst, J. Cortes, P. Schmid, et al. · Mayo Clinic
    Trials in Progress Poster SessionBreast Cancer—Metastatic📄🖼️
  121. Abstract 11852026-09-01 · 14:30 CT · Arie Crown Theater
    Long-term follow-up of Ibrance 1L for HR+ breast cancer: PALOMA-815
    E. Winer, N. Rizvi, S. Antonia · National Cancer Center Japan
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  122. Abstract 11602026-09-02 · 20:15 CT · S100A
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-262
    P. Schmid, F. Andre, S. Peters, et al. · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  123. Abstract 17062026-09-02 · 18:45 CT · S100A
    Long-term follow-up of Ibrance 2L for HR+ breast cancer: PALOMA-191
    C. Saura, J. Brahmer, A. Spira · Vall d'Hebron Institute of Oncology
    Poster SessionBreast Cancer—Metastatic📄🖼️
  124. Abstract 17692026-09-04 · 14:30 CT · Hall B1
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-943 study)
    A. Spira, R. Herbst, C. Robert, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  125. Abstract 14822026-09-04 · 13:30 CT · Hall B1
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-225 study)
    L. Paz-Ares, S. Modi · Mayo Clinic
    Education SessionBreast Cancer—Metastatic📄🖼️
  126. Abstract 14632026-09-05 · 15:30 CT · S100A
    Keytruda plus chemotherapy in previously untreated TNBC: updated analysis from KEYNOTE-155
    E. Winer, T. Mok, P. Schmid, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  127. Abstract 11112026-09-02 · 19:15 CT · S406
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-123 study)
    F. Andre, M. Krop · Mayo Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  128. Abstract 14052026-09-05 · 21:15 CT · S100A
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-5 study)
    H. Rugo, S. Tolaney, M. Reck, et al. · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  129. Abstract 14492026-09-04 · 18:45 CT · E450
    Long-term follow-up of Trodelvy adjuvant for TNBC: ASCENT-223
    R. Herbst, P. Schmid, J. Brahmer · Karolinska Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  130. Abstract 19552026-09-05 · 15:45 CT · Hall B1
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-784 study)
    S. Modi, L. Paz-Ares, F. Andre, et al. · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  131. Abstract 17052026-09-01 · 14:00 CT · E450
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-461 study)
    M. Reck, J. Brahmer, A. Spira · Princess Margaret Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  132. Abstract 15302026-09-05 · 13:45 CT · Arie Crown Theater
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-937
    C. Robert, F. Andre, J. Cortes, et al. · Stanford Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  133. Abstract 16312026-09-02 · 14:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-121 study)
    F. Andre, C. Saura · MD Anderson Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  134. Abstract 11952026-09-05 · 14:45 CT · E450
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-912 study)
    C. Robert, S. Antonia, R. Herbst · Chinese University of Hong Kong
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  135. Abstract 18342026-09-03 · 18:45 CT · E450
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-920
    P. Schmid, S. Antonia, C. Robert, et al. · Institut Gustave Roussy
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  136. Abstract LBA4135LBA2026-09-04 · 15:15 CT · E450
    Keytruda plus chemotherapy in previously untreated TNBC: updated analysis from KEYNOTE-811
    H. Rugo, J. Brahmer · Mayo Clinic
    Late-Breaking Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  137. Abstract 11612026-09-05 · 20:30 CT · Hall B1
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-479
    S. Antonia, J. Brahmer, H. Borghaei, et al. · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  138. Abstract 12552026-09-05 · 21:15 CT · E450
    Long-term follow-up of Verzenio 2L for HR+ breast cancer: MONARCH-72
    T. Mok, C. Robert, H. Borghaei, et al. · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  139. Abstract e121382026-09-05 · 16:45 CT · S406
    Biomarker subgroup analysis of Enhertu in HR+ breast cancer (the DESTINY-Breast-769 study)
    P. Schmid, M. Reck, H. Rugo, et al. · University of Chicago
    Publication OnlyBreast Cancer—Metastatic📄🖼️
  140. Abstract 13902026-09-04 · 13:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-308 study)
    R. Herbst, M. Reck, J. Cortes, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  141. Abstract 17432026-09-03 · 16:00 CT · E450
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-745
    L. Paz-Ares, N. Rizvi · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  142. Abstract 11712026-09-01 · 15:45 CT · Arie Crown Theater
    IMpower-603: Tecentriq (atezolizumab) 2L in TNBC
    M.C. Garassino, S. Antonia, S. Tolaney · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  143. Abstract 10442026-09-01 · 21:00 CT · E450
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-889 study)
    J. Cortes, C. Robert, M. Krop · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  144. Abstract 10002026-09-04 · 16:30 CT · E450
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-354
    G. Curigliano, S. Modi, F. Andre, et al. · Institut Gustave Roussy
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  145. Abstract 15302026-09-04 · 20:30 CT · Hall B1
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-242
    P. Schmid, H. Rugo, J. Cortes, et al. · MD Anderson Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  146. Abstract 13332026-09-02 · 20:00 CT · S100A
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-89 study)
    G. Curigliano, S. Peters, M. Krop, et al. · Chinese University of Hong Kong
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  147. Abstract 15572026-09-03 · 13:15 CT · S100A
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-7 study)
    P. Schmid, S. Peters · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  148. Abstract 12782026-09-02 · 20:00 CT · S100A
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-959
    P. Schmid, H. Rugo · Stanford Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  149. Abstract 18472026-09-05 · 19:45 CT · S406
    MONARCH-532: Verzenio (abemaciclib) adjuvant in HR+ breast cancer
    M. Krop, T. Mok, M. Reck, et al. · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  150. Abstract 14502026-09-01 · 15:00 CT · E450
    Long-term follow-up of Verzenio 2L for HR+ breast cancer: MONARCH-15
    J. Brahmer, S. Peters, G. Curigliano, et al. · University of Chicago
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  151. Abstract 11722026-09-05 · 21:00 CT · S406
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-477
    H. Borghaei, M. Reck, S. Modi · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  152. Abstract 13112026-09-02 · 15:00 CT · Arie Crown Theater
    PALOMA-389: Ibrance (palbociclib) 3L+ in HR+ breast cancer
    H. Borghaei, F. Andre, C. Robert, et al. · Chinese University of Hong Kong
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  153. Abstract 13542026-09-05 · 20:00 CT · S100A
    PALOMA-980: Ibrance (palbociclib) 2L in HR+ breast cancer
    R. Herbst, S. Modi, P. Schmid, et al. · Mayo Clinic
    Education SessionBreast Cancer—Metastatic📄🖼️
  154. Abstract 17492026-09-03 · 19:45 CT · Arie Crown Theater
    Long-term follow-up of Kisqali 3L+ for HR+ breast cancer: MONALEESA-765
    S. Modi, G. Curigliano, H. Borghaei, et al. · Royal Marsden Hospital
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  155. Abstract 11242026-09-03 · 16:30 CT · Arie Crown Theater
    MONARCH-413: Verzenio (abemaciclib) neoadjuvant in HR+ breast cancer
    M. Reck, S. Tolaney, S. Peters, et al. · University of Chicago
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  156. Abstract 13232026-09-01 · 14:15 CT · S100A
    MONARCH-776: Verzenio (abemaciclib) 2L in HR+ breast cancer
    M. Krop, H. Borghaei, C. Saura · Vall d'Hebron Institute of Oncology
    Poster SessionBreast Cancer—Metastatic📄🖼️
  157. Abstract 17662026-09-03 · 21:15 CT · Hall B1
    MONARCH-970: Verzenio (abemaciclib) 1L in HR+ breast cancer
    J. Cortes, N. Rizvi, E. Winer, et al. · Peter MacCallum Cancer Centre
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  158. Abstract 13112026-09-01 · 15:45 CT · S100A
    Long-term follow-up of Kisqali 3L+ for HR+ breast cancer: MONALEESA-660
    M. Reck, F. Andre · Karolinska Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  159. Abstract LBA4158LBA2026-09-01 · 20:00 CT · S406
    MONARCH-189: Verzenio (abemaciclib) 1L in HR+ breast cancer
    L. Paz-Ares, J. Cortes, H. Rugo, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Late-Breaking Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  160. Abstract 15782026-09-02 · 19:30 CT · S100A
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-5
    S. Antonia, H. Rugo, L. Paz-Ares, et al. · Princess Margaret Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  161. Abstract e121602026-09-05 · 14:30 CT · S100A
    Long-term follow-up of Trodelvy 3L+ for TNBC: ASCENT-252
    C. Saura, J. Brahmer, S. Modi, et al. · National Cancer Center Japan
    Publication OnlyBreast Cancer—Metastatic📄🖼️
  162. Abstract 14342026-09-03 · 19:15 CT · S100A
    IMpower-455: Tecentriq (atezolizumab) 3L+ in TNBC
    S. Modi, R. Herbst, N. Rizvi · Massachusetts General Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  163. Abstract 15642026-09-02 · 16:45 CT · E450
    MONALEESA-35: Kisqali (ribociclib) adjuvant in HR+ breast cancer
    M.C. Garassino, L. Paz-Ares, S. Peters, et al. · MD Anderson Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  164. Abstract 16832026-09-01 · 14:15 CT · S100A
    DESTINY-Breast-207: Enhertu (trastuzumab deruxtecan) 1L in HR+ breast cancer
    G. Curigliano, M. Krop, R. Herbst, et al. · Mayo Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  165. Abstract 11072026-09-04 · 13:30 CT · E450
    MONALEESA-110: Kisqali (ribociclib) 3L+ in HR+ breast cancer
    S. Antonia, C. Saura, L. Paz-Ares · Royal Marsden Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  166. Abstract 19542026-09-05 · 15:45 CT · Hall B1
    Tecentriq plus chemotherapy in previously untreated TNBC: updated analysis from IMpower-121
    T. Mok, J. Brahmer, M. Reck · Vall d'Hebron Institute of Oncology
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  167. Abstract e121662026-09-04 · 15:45 CT · S406
    OlympiA-948: Lynparza (olaparib) 1L in HR+ breast cancer
    S. Tolaney, J. Brahmer, M. Reck, et al. · National Cancer Center Japan
    Publication OnlyBreast Cancer—Metastatic📄🖼️
  168. Abstract 18122026-09-05 · 21:45 CT · Hall B1
    MONARCH-441: Verzenio (abemaciclib) neoadjuvant in HR+ breast cancer
    T. Mok, N. Rizvi · Institut Gustave Roussy
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  169. Abstract 13272026-09-03 · 20:30 CT · Hall B1
    Long-term follow-up of Tecentriq neoadjuvant for TNBC: IMpower-555
    H. Rugo, S. Tolaney, C. Saura, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  170. Abstract 18452026-09-02 · 19:45 CT · E450
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-733 study)
    M. Reck, M. Krop, H. Rugo, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  171. Abstract 16602026-09-03 · 13:30 CT · S100A
    KEYNOTE-629: Keytruda (pembrolizumab) 1L in TNBC
    H. Borghaei, M. Reck, J. Brahmer, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  172. Abstract 17752026-09-01 · 13:45 CT · Arie Crown Theater
    MONARCH-409: Verzenio (abemaciclib) 3L+ in HR+ breast cancer
    L. Paz-Ares, H. Borghaei · Chinese University of Hong Kong
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  173. Abstract 17082026-09-01 · 19:15 CT · E450
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-430 study)
    S. Peters, F. Andre · Princess Margaret Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  174. Abstract 16622026-09-02 · 14:45 CT · Arie Crown Theater
    PALOMA-292: Ibrance (palbociclib) maintenance in HR+ breast cancer
    S. Antonia, C. Robert, J. Brahmer · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  175. Abstract 17272026-09-02 · 19:00 CT · S100A
    Tecentriq plus chemotherapy in previously untreated TNBC: updated analysis from IMpower-87
    S. Peters, P. Schmid · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  176. Abstract 19692026-09-02 · 13:30 CT · Arie Crown Theater
    PALOMA-547: Ibrance (palbociclib) 2L in HR+ breast cancer
    M. Reck, C. Saura · MD Anderson Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  177. Abstract 15932026-09-04 · 20:30 CT · E450
    Long-term follow-up of Kisqali 3L+ for HR+ breast cancer: MONALEESA-276
    C. Robert, S. Peters · Mayo Clinic
    Education SessionBreast Cancer—Metastatic📄🖼️
  178. Abstract 11352026-09-04 · 18:15 CT · Hall B1
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-335 study)
    S. Antonia, J. Brahmer, C. Saura, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  179. Abstract 14582026-09-03 · 21:15 CT · Arie Crown Theater
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-339
    M. Krop, H. Borghaei · Chinese University of Hong Kong
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  180. Abstract 11702026-09-04 · 16:45 CT · Arie Crown Theater
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-394
    T. Mok, S. Tolaney, M. Reck, et al. · Princess Margaret Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  181. Abstract 18982026-09-02 · 19:30 CT · S406
    Long-term follow-up of Kisqali maintenance for HR+ breast cancer: MONALEESA-387
    J. Cortes, M.C. Garassino, H. Rugo, et al. · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  182. Abstract 10022026-09-05 · 16:00 CT · E450
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-853 study)
    H. Borghaei, A. Spira, H. Rugo, et al. · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  183. Abstract 17392026-09-03 · 18:30 CT · S406
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-762
    E. Winer, S. Tolaney · Chinese University of Hong Kong
    Poster SessionBreast Cancer—Metastatic📄🖼️
  184. Abstract 10042026-09-02 · 14:30 CT · S100A
    Biomarker subgroup analysis of Lynparza in HR+ breast cancer (the OlympiA-776 study)
    M. Reck, C. Robert, T. Mok, et al. · MD Anderson Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  185. Abstract 11132026-09-01 · 21:30 CT · S406
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-446
    S. Tolaney, M. Reck · Vall d'Hebron Institute of Oncology
    Poster SessionBreast Cancer—Metastatic📄🖼️
  186. Abstract 10872026-09-02 · 19:30 CT · E450
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-44
    E. Winer, N. Rizvi · Stanford Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  187. Abstract 15422026-09-01 · 16:00 CT · Hall B1
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-292
    G. Curigliano, T. Mok, J. Cortes, et al. · Royal Marsden Hospital
    Education SessionBreast Cancer—Metastatic📄🖼️
  188. Abstract 14172026-09-01 · 21:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-779 study)
    C. Saura, E. Winer, M.C. Garassino · Massachusetts General Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  189. Abstract 17232026-09-03 · 14:15 CT · Hall B1
    ASCENT-729: Trodelvy (sacituzumab govitecan) 3L+ in TNBC
    H. Borghaei, G. Curigliano, S. Tolaney, et al. · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  190. Abstract 10572026-09-05 · 19:15 CT · E450
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-56 study)
    S. Modi, H. Borghaei, N. Rizvi, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  191. Abstract LBA4190LBA2026-09-03 · 21:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-587 study)
    H. Rugo, S. Modi, P. Schmid, et al. · National Cancer Center Japan
    Late-Breaking Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  192. Abstract TPS81912026-09-03 · 19:15 CT · Hall B1
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-312
    H. Rugo, A. Spira, S. Tolaney · Stanford Cancer Institute
    Trials in Progress Poster SessionBreast Cancer—Metastatic📄🖼️
  193. Abstract 19582026-09-01 · 13:15 CT · Arie Crown Theater
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-848
    P. Schmid, L. Paz-Ares, M. Krop, et al. · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  194. Abstract 12712026-09-04 · 13:45 CT · E450
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-428
    A. Spira, M.C. Garassino · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  195. Abstract 11512026-09-01 · 15:15 CT · Hall B1
    MONALEESA-992: Kisqali (ribociclib) 3L+ in HR+ breast cancer
    T. Mok, H. Rugo, S. Peters · Chinese University of Hong Kong
    Poster SessionBreast Cancer—Metastatic📄🖼️
  196. Abstract 19472026-09-04 · 21:00 CT · E450
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-254
    S. Antonia, C. Robert, M. Reck · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  197. Abstract 14952026-09-05 · 16:45 CT · Arie Crown Theater
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-60
    F. Andre, E. Winer, H. Borghaei, et al. · Peter MacCallum Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  198. Abstract 16962026-09-01 · 20:15 CT · Hall B1
    ASCENT-711: Trodelvy (sacituzumab govitecan) adjuvant in TNBC
    P. Schmid, F. Andre, M.C. Garassino · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  199. Abstract 12792026-09-05 · 16:30 CT · Arie Crown Theater
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-865
    S. Peters, G. Curigliano, P. Schmid · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  200. Abstract 11222026-09-04 · 19:00 CT · S100A
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-286 study)
    S. Tolaney, M.C. Garassino · National Cancer Center Japan
    Education SessionBreast Cancer—Metastatic📄🖼️
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.